Comments to Senate Finance Committee call for a U.S.-specific framework that aligns affordability, access, and innovation around the outcomes that matter to patients and families.
IVI today submitted comments to Senate Finance Committee Ranking Member Ron Wyden urging policymakers to address lower prescription drug prices, reduced patient out-of-pocket costs, and sustained biopharmaceutical innovation as interconnected goals—not competing priorities.
IVI calls for drug pricing reform to begin with a shared definition of patient- and family-centered value and introduces Patient + Whole Family Health (PWFH), a framework designed to center healthcare decision-making on the outcomes that matter to patients, families, and caregivers. The comments outline initial policy domains and guardrails to guide the development of a U.S.-specific approach that aligns affordability, access, innovation, and long-term sustainability.
IVI also cautions against piecemeal reforms and importing pricing or value assessment models designed for single-payer healthcare systems that do not reflect the complexity of the U.S. multi-payer system.